Not finding it? Sign in to also search OpenAlex live.
-
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy2025 Arteriosclerosis Thrombosis and Vascular Biology article Medicine Lipoproteins and Cardiovascular Health Open access
Esther Reijnders, Patrick M. Bossuyt, J. Wouter Jukema, L. Renee Ruhaak, Fred P.H.T.M. Romijn, Michael J. Szarek, +12 more
6citations -
Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction2026 Pharmacoepidemiology and Drug Safety article Mathematics Advanced Causal Inference Techniques Open access
Thomas Cars, Stefan Gustafsson, Queenie M Chan, Nafeesa N Dhalwani, Shia T. Kent, Chris P Gale, +7 more
0citations -
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation2024 European Heart Journal - Cardiovascular Pharmacotherapy article Medicine Lipoproteins and Cardiovascular Health Open access
Shaun G. Goodman, Philippe Gabríel Steg, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, +61 more
25citations -
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol2021 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo, Garen Z. Manvelian, Robert C. Pordy, Michel Scemama, +61 more
147citations -
Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice2021 Osteoarthritis and Cartilage article Medicine Osteoarthritis Treatment and Mechanisms Open access
Yvonne van Gemert, A.E. Kozijn, Marianne G. Pouwer, N.N.L. Kruisbergen, Martijn H. J. van den Bosch, Arjen B. Blom, +4 more
13citations -
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
José Tuñón, Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, +11 more
76citations -
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Gregory G. Schwartz, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, Maja Bujas‐Bobanovic, Rafael Díaz, +11 more
47citations -
Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study2023 The Lancet Regional Health - Europe article Medicine Lipoproteins and Cardiovascular Health Open access
Julia Brandts, Sarah L Bray, Guillermo Villa, Alberico Luigi Catapano, Neil R Poulter, Antonio J. Vallejo‐Vaz, +1 more
45citations -
L ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German–Austrian diabetes registry2023 Diabetes Obesity and Metabolism article Medicine Lipoproteins and Cardiovascular Health Open access
Julia Brandts, Sascha René Tittel, Peter Bramlage, Thomas Danne, Johanna Maria Brix, Stefan Zimny, +3 more
30citations -
Abstract 13567: Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES
Michael J. Szarek, Esther Reijnders, Philippe Gabríel Steg, J. Wouter Jukema, Markus Schwertfeger, Deepak L. Bhatt, +10 more
0citations -
A placebo‐controlled proof‐of‐concept study of alirocumab on postprandial lipids and vascular elasticity in insulin‐treated patients with type 2 diabetes mellitus2020 Diabetes Obesity and Metabolism article Medicine Lipoproteins and Cardiovascular Health Open access
Benjamin Burggraaf, Nadine M. C. Pouw, Salvador Fernández‐Arroyo, Leonie C. van Vark‐van der Zee, Gert‐Jan M. van de Geijn, Erwin Birnie, +6 more
20citations